eCommons@AKU
Community Health Sciences

Department of Community Health Sciences

4-2020

Association of dairy consumption with metabolic syndrome,
hypertension and diabetes in 147 812 individuals from 21
countries
Balaji Bhavadharini
Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada

Mahshid Dehghan
Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada

Andrew Mente
Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada

Sumathy Rangarajan
Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada

Patrick Sheridan
Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_chs_chs
See next page for additional authors
Part of the Cardiovascular Diseases Commons, Community Health and Preventive Medicine
Commons, Endocrine System Diseases Commons, Endocrinology, Diabetes, and Metabolism Commons,
Epidemiology Commons, Health Services Research Commons, and the Nutritional and Metabolic
Diseases Commons

Recommended Citation
Bhavadharini, B., Dehghan, M., Mente, A., Rangarajan, S., Sheridan, P., Mohan, V., Iqbal, R., Gupta, R., Lear,
S., Wentzel-Viljoen, E. (2020). Association of dairy consumption with metabolic syndrome, hypertension
and diabetes in 147 812 individuals from 21 countries. BMJ Open Diabetes Research and Care, 8(1),
e000826- .
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_chs_chs/758

Authors
Balaji Bhavadharini, Mahshid Dehghan, Andrew Mente, Sumathy Rangarajan, Patrick Sheridan,
Viswanathan Mohan, Romaina Iqbal, Rajeev Gupta, Scott Lear, and Edelweiss Wentzel-Viljoen

This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_chs_chs/758

Open access

Original research

Association of dairy consumption with
metabolic syndrome, hypertension and
diabetes in 147 812 individuals from
21 countries
Balaji Bhavadharini  ,1 Mahshid Dehghan,1 Andrew Mente  ,1,2
Sumathy Rangarajan,1 Patrick Sheridan,1 Viswanathan Mohan,3,4 Romaina Iqbal,5
Rajeev Gupta,6 Scott Lear,7 Edelweiss Wentzel-Viljoen,8 Alvaro Avezum,9
Patricio Lopez-Jaramillo,10 Prem Mony,11 Ravi Prasad Varma,12 Rajesh Kumar,13
Jephat Chifamba,14 Khalid F Alhabib,15 Noushin Mohammadifard,16
Aytekin Oguz,17 Fernando Lanas,18 Dorota Rozanska,19
Kristina Bengtsson Bostrom,20 Khalid Yusoff,21 Lungiswa P Tsolkile,22
Antonio Dans,23 Afzalhussein Yusufali  ,24 Andres Orlandini,25 Paul Poirier  ,26
Rasha Khatib,27 Bo Hu,28 Li Wei  ,29 Lu Yin,28 Ai Deeraili,30 Karen Yeates,31
Rita Yusuf,32 Noorhassim Ismail,33 Dariush Mozaffarian,34 Koon Teo,1,2,35
Sonia S Anand,1,2,35 Salim Yusuf1,2,35

To cite: Bhavadharini B,
Dehghan M, Mente A,
et al. Association of dairy
consumption with metabolic
syndrome, hypertension
and diabetes in 147 812
individuals from 21 countries.
BMJ Open Diab Res Care
2020;8:e000826. doi:10.1136/
bmjdrc-2019-000826
►► Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
bmjdrc-2019-000826).

Received 14 August 2019
Revised 7 January 2020
Accepted 22 January 2020

© Author(s) (or their
employer(s)) 2020. Re-use
permitted under CC BY-NC. No
commercial re-use. See rights
and permissions. Published
by BMJ.
For numbered affiliations see
end of article.
Correspondence to
Dr Andrew Mente;
andrew.mente@phri.ca

Abstract

Objective Our aims were to assess the association of
dairy intake with prevalence of metabolic syndrome (MetS)
(cross-sectionally) and with incident hypertension and
incident diabetes (prospectively) in a large multinational
cohort study.
Methods The Prospective Urban Rural Epidemiology
(PURE) study is a prospective epidemiological study of
individuals aged 35 and 70 years from 21 countries on
five continents, with a median follow-up of 9.1 years. In
the cross-sectional analyses, we assessed the association
of dairy intake with prevalent MetS and its components
among individuals with information on the five MetS
components (n=112 922). For the prospective analyses,
we examined the association of dairy with incident
hypertension (in 57 547 individuals free of hypertension)
and diabetes (in 131 481 individuals free of diabetes).
Results In cross-sectional analysis, higher intake of
total dairy (at least two servings/day compared with zero
intake; OR 0.76, 95% CI 0.71 to 0.80, p-trend<0.0001)
was associated with a lower prevalence of MetS after
multivariable adjustment. Higher intakes of whole fat
dairy consumed alone (OR 0.72, 95% CI 0.66 to 0.78,
p-trend<0.0001), or consumed jointly with low fat dairy
(OR 0.89, 95% CI 0.80 to 0.98, p-trend=0.0005), were
associated with a lower MetS prevalence. Low fat dairy
consumed alone was not associated with MetS (OR
1.03, 95% CI 0.77 to 1.38, p-trend=0.13). In prospective
analysis, 13 640 people with incident hypertension and
5351 people with incident diabetes were recorded. Higher
intake of total dairy (at least two servings/day vs zero
serving/day) was associated with a lower incidence of
hypertension (HR 0.89, 95% CI 0.82 to 0.97, p-trend=0.02)
and diabetes (HR 0.88, 95% CI 0.76 to 1.02, p-trend=0.01).
Directionally similar associations were found for whole fat
dairy versus each outcome.

Significance of this study
What is already known about this subject?
►► Several cohort studies found that higher dairy in-

take is associated with lower risk of metabolic syndrome (MetS), diabetes, and hypertension. To date,
most studies were conducted in North America and
Europe, with limited information from other world
regions (eg, China, India, South America, and Africa).

What are the new findings?
►► Higher intake of whole fat (but not low fat) dairy was

associated with a lower prevalence of MetS and
most of its component factors, and with a lower incidence of hypertension and diabetes.

How might these results change the focus of
research or clinical practice?
►► Our findings should be evaluated in large random-

ized trials of the effects of whole fat dairy on the
risks of MetS, hypertension, and diabetes.

Conclusions Higher intake of whole fat (but not low fat)
dairy was associated with a lower prevalence of MetS and
most of its component factors, and with a lower incidence
of hypertension and diabetes. Our findings should be
evaluated in large randomized trials of the effects of whole
fat dairy on the risks of MetS, hypertension, and diabetes.

Introduction
Metabolic syndrome (MetS) is characterized
by the common clustering of five metabolic
abnormalities, including elevated blood
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pressure, abdominal obesity, elevated triglycerides, low
high density lipoprotein (HDL) cholesterol, and elevated
blood glucose. The presence of MetS is associated with an
increased risk of cardiovascular disease, type 2 diabetes,
and mortality.1 Diet may play an important role in the
development of MetS and diabetes.2–4 Dairy products in
particular have been studied in relation to blood lipids,
blood pressure, and cardiovascular disease.5 In several
short-term trials, dairy intake was found to lower blood
pressure,6 7 but less is known about its influence on blood
glucose.8 9 Emerging evidence suggests that dairy foods,
particularly whole fat dairy and fermented dairy (eg,
cheese or yogurt), may influence diverse pathways and
have favorable metabolic effects.10 Additionally, several
cohort studies have shown that higher dairy consumption is associated with lower risk of MetS, diabetes, and
hypertension.5 11 12 To date, most cohort studies have
been conducted in North America and Europe, with
limited information from other world regions (eg, China,
India, South America, and Africa), which have substantially different diets and different amounts and types of
dairy intake than in high income countries and may limit
the generalizability of previous findings.
The primary aim of this analysis from the Prospective
Urban Rural Epidemiology (PURE) study was to assess
the association of dairy intake with prevalence of MetS
(cross -sectional analysis) and to examine the association of dairy intake with incident hypertension and incident diabetes after 9.1 years of follow-up (prospective
analyses).
Methods
Study design and participants
The design and methods of the PURE study have been
described previously.13 14 Briefly, PURE is a large-scale
cohort study of participants aged 35 and 70 years using
an unbiased approach of sampling individuals from 664
communities in 21 countries (Argentina, Bangladesh,
Brazil, Canada, Chile, China, Colombia, India, Iran,
Malaysia, occupied Palestine territory, Pakistan, Philippines, Poland, South Africa, Saudi Arabia, Sweden,
Tanzania, Turkey, United Arab Emirates, and Zimbabwe).
Details of study design and sampling are described in
online supplementary appendix (page 10). The protocol
was approved by the ethics committee at each participating center and all participants provided written
informed consent.
Procedures
Participants’ habitual food intake was recorded using
country-specific (region-specific in India) validated food
frequency questionnaires (FFQs; online appendix table
S1). For almost all countries where a validated FFQ was
not available, we developed and validated FFQs using
a standard method. The FFQ was undertaken by interview together with other questionnaires at the PURE
study baseline. The FFQ recorded the number of times
2

participants had consumed any specific items from a list
of foods in the past year. The FFQs had the same format
for all countries. Total dairy included milk, yogurt, yogurt
drink, cheese, and mixed dishes prepared with dairy.
Mixed dishes prepared with dairy were disaggregated
into their constituents and a proportional weight was
assigned to each component. We further grouped these
foods into whole fat dairy (whole milk, whole fat yogurt,
whole fat cheese, whole fat yogurt drinks, and mixed
dishes prepared with whole f at dairy products) and
low fat dairy (low fat (1–2%) milk, skimmed milk, low
fat yogurt, low fat cheese, and low fat yogurt drink). To
ensure that measurements were consistent across countries we used daily standard serving intake of each dairy
product. Butter and cream were not included in the total
dairy and whole fat dairy groups and their associations
are reported separately. Butter intake was not recorded
as an item on the FFQ in China, Malaysia, Sweden, and
occupied Palestine territory, and therefore, the association between butter and outcomes was assessed only in
those countries where butter intake was recorded.
Information on personal medical history, use of
prescription medications, education level, and smoking
status was recorded using a standardized questionnaire.13 14 Physical measurements included weight,
height, waist and hip circumferences, and two recordings of resting blood pressure with the use of an Omron
HEM-757 automatic digital monitor (Omron Corp,
Tokyo, Japan) were recorded in all participants. A fasting
blood sample was collected and frozen at between –20
and –70°C. All blood samples were shipped in ambient
packaging with the use of STP-250 shipping boxes (Saf-
T-Pak, AnInmark Company, Edmonton, AB, Canada) to
the Clinical Research and Clinical Trials Laboratory at
Hamilton General Hospital (Hamilton, ON, Canada) or
the regional laboratories in Beijing (China), Bangalore
(India), or Kocaeli (Turkey), for analyses with the use
of validated and standardized methods.15 Fasting blood
samples were analyzed for total cholesterol, low density
lipoprotein cholesterol (LDL-C), HDL cholesterol (HDL-
C), triglycerides, apolipoprotein A1, and apolipoprotein
B at the Population Health Research Institute.16
During follow-up, participants were contacted at least
once every three years either by telephone or in person
visits by the local research team. Case-
report forms
recorded details about events and these were obtained
either from medical records or by interviewing participants. During the follow-
up, participants were asked
if they had been diagnosed with hypertension or were
on antihypertensive medications. Participants were
also asked if they had developed diabetes since the last
follow-
up (self-
reported diabetes, or on oral hypoglycemic agents). We did not record lipids or waist circumference routinely during follow-up in all individuals and
so we are not able to report on incident MetS.
A total of 153 220 participants from 21 countries
completed the FFQ at baseline, of whom 147 812 had
plausible energy intake (500–5000 kcal/day).17–19 For
BMJ Open Diab Res Care 2020;8:e000826. doi:10.1136/bmjdrc-2019-000826
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the cross-sectional analysis, among individuals with information on the five MetS components (n=112 922), we
assessed the association of dairy intake with prevalent
MetS and its components. For the prospective analysis, we
examined the association of dairy with incident hypertension (n=57 547 individuals free of hypertension) and
diabetes (n=131 481 individuals free of diabetes) after 9.1
years of follow-up. The analysis of incident hypertension
included fewer individuals because 64 978 individuals or
44% who had hypertension at baseline were no longer
at risk for incident hypertension during follow-up. Of
the 82 834 participants without baseline hypertension,
25 287 (30%) were excluded because blood pressure was
not recorded in all participants during follow-up. The
blood pressure measures during follow-up were carried
out systematically in all participants in 16 countries or
in a random 20% of participants in five countries. In
the latter group of countries, the individuals without
blood pressure measures during follow-up did not differ
from individuals with blood pressure measures during
follow-up (online appendix table S2).
Outcome definitions
The MetS was determined based on five component
factors: (1) elevated blood pressure, (2) elevated waist
circumference, (3) low HDL-
C), (4) elevated blood
triglycerides, and (5) elevated fasting blood glucose.
Participants with at least three of the following five
component factors were classified as having MetS at
baseline.1
1. Elevated blood pressure: blood pressure lowering
medication or systolic blood pressure (SBP)≥130 mm
Hg, or diastolic blood pressure (DBP)≥85 mm Hg.
2. Elevated waist circumference: waist greater than 80 cm
in women, and at least 94 cm in men (except among
Asians or South Americans in whom a waist circumference of ≥90 cm was used).
3. Reduced HDL-
C: HDL-
C<1 mmol/dL (40 mg/dL)
among men or HDL-
C<1.3 mmol/L (50 mg/dL)
among women.
4. Elevated triglycerides: triglycerides>1.7 mmmol/dL
(150 mg/dL).
5. Elevated fasting blood glucose: fasting glucose≥5.5 mmol/L (100 mg/dL) or those on oral hypoglycemic agents.
Metabolic syndrome was defined as the presence of
any three of the above five components.1
During follow-up, incident hypertension was defined
as self-reported diagnosis of hypertension or prescribed
antihypertensive medications, or having a SBP>140 mm
Hg or a DBP>90 mm Hg.20 Incident diabetes was
defined as self-reported diabetes, or prescribed an oral
hypoglycemic agents, or having a fasting glucose of
≥7.0 mmol/L).21
Statistical analysis
Continuous variables were expressed as means (SD)
and categorical variables as percentages. Education was
BMJ Open Diab Res Care 2020;8:e000826. doi:10.1136/bmjdrc-2019-000826

categorized as none or primary school (first 6 years of
age), secondary school (7–11 years of age), and college,
trade school, or university (>11 years of age). Smoking
status was categorized as never, former, or current. Physical activity was categorized based on the metabolic
equivalent of task (MET) per min per week into low
(<600 MET min per week), moderate (600–3000 MET
min per week), and high (>3000 MET min per week)
activity. The mean and median intakes of total dairy were
calculated, overall and by geographical region. Participants were categorized into intake groups based on total
dairy intakes of zero, less than one serving/day, one to
two servings/day, and more than two servings/day (with
the lowest intake group used as the reference). Categories
for milk, yogurt, cheese, and butter consumption were
zero, less than half a serving/day, half to one serving/
day, and more than one serving/day. We used standard
serving sizes for each dairy product. For example, a
glass of milk or a cup of yogurt was 244 g, one slice of
cheese was 15 g, and a teaspoon of butter was 5 g.19 In the
cross-sectional analyses, we used multilevel mixed-effects
linear regression models to calculate the adjusted mean
SBP and DBP, waist circumference, blood lipids (LDL-C,
HDL-C, triglycerides, apolipoprotein A, apolipoprotein
B, ratio of apolipoprotein B to apolipoprotein A), and
fasting glucose at baseline by category of dairy intake
using multilevel mixed-effects linear regression models.
Odds ratios were calculated to evaluate the associations
between dairy intake and MetS, and each component
of MetS (elevated blood pressure, low HDL-C, elevated
waist circumference, elevated triglycerides, and elevated
blood glucose) using logistic regression models. For
models of each individual component of MetS except
for waist circumference, we adjusted for age (continuous
variable), sex, body mass index (continuous variable),
smoking status, urban or rural residence, education, physical activity, energy intake, quintiles of fruits, vegetables,
and percent energy from carbohydrate consumption, and
study center (as a random intercept). The use of center
as a random intercept takes into account clustering by
country (which automatically adjusts for country, and
more specifically, centers within each country). For waist
circumference and MetS, we ran the same model but
excluded body mass index, to avoid collinearity. When we
evaluated intakes of starchy foods as a covariate in place
of percent energy from carbohydrates, findings were not
materially altered (online appendix table S3).
For the prospective data, we calculated hazard ratios
using multivariable Cox frailty model with random intercepts to account for center clustering (which also adjusts
for country) to evaluate the association of dairy intake
with incident hypertension and incident diabetes. Multivariable models for incident hypertension and incident
diabetes were adjusted for age (continuous variable),
sex, body mass index (continuous variable), education,
smoking status, urban or rural residence (location), physical activity, energy intake, quintiles of percent energy
from carbohydrates, vegetable and fruit intake, and study
3
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center as random intercept. For incident diabetes, we
additionally adjusted for family history of diabetes. The
proportional hazards assumption was checked by visual
inspection of log–log plots. We used restricted cubic-
spline analyses to test for non-linearity of the association
between dairy intake and incident diabetes. For significant non-
linear associations, the p values for overall
significance of the association is reported, whereas associations with no evidence of non-linearity were characterized by tests for linear trend.
Since the amount and types of dairy foods differ across
world regions (eg, intake of dairy is highest in Europe and
North America, South America and the Middle East, and
lowest in China, South Asia, Southeast Asia, and Africa),
we conducted subgroup analyses to examine associations
between dairy and outcome events according to low
versus high dairy intake regions. Additionally, we examined whether the associations were similar across seven
geographical regions, among those consuming higher or
lower levels of sodium or potassium and those consuming
higher or lower servings of fruits and vegetables, as these
factors may influence associations with MetS, hypertension, and diabetes. The likelihood ratio test was used to
test for heterogeneity of associations across subgroups.
In sensitivity analyses, to assess the association between
whole fat and low fat dairy intake with outcomes, participants were stratified based on the predominant type of
dairy intake and four mutually exclusive groups were
created. In our FFQs, the frequency of consumption as
never or less than once per month was used as an indicator for food items never or rarely consumed. Therefore,
whole fat dairy intake was defined as an intake of whole
fat dairy of one serving or more per month and an intake
of low fat dairy of less than one serving per month. Intake
of more than one serving of low fat dairy per month and
less than one serving of whole fat dairy per month was
defined as low fat dairy intake. However, our study was
underpowered to detect an association separately in this
subgroup owing to a low number of participants in this
particular group. Both low fat and whole fat dairy intakes
were defined as intake of at least one serving of whole
fat dairy and one serving of low fat dairy per month.
Individuals whose intake of dairy was reported to be less
than once per month or never were considered as having
no intake. In each group, the lowest intake was used as
the reference group. Models for whole dairy intake are
adjusted for low fat dairy intake and vice versa.
For risk estimates showing relative risk decrease or
increase of more than 10% (eg, HR<0.90 or >1.10)
but with a non-significant p-value for trend, we considered estimates to be directionally associated with health
outcomes. This magnitude threshold was used to reflect
the strength of association expected for dietary exposures versus metabolic risk markers or outcomes, and
would be of importance for population health. In tests
for trend, we used the median dairy intake value in each
of the categories of dairy intake and included the variable as a quantitative predictor.
4

Role of the funding source
The external funders of the study had no role in study
design, data collection, analysis, interpretation, or writing
of the report. The corresponding and senior authors
had full access to all the data in the study and had final
responsibility for the decision to submit for publication.

Results
Mean (±SD) total dairy intake was 179.0 (224.1) g/day,
with whole fat dairy consumption almost twice as high
as low fat dairy intake (124.6 vs 65.0 g/day) (table 1).
Highest intakes of total dairy were found in Europe/
North America, Middle East, and South America, while
the lowest intakes were in South Asia, China, Africa, and
Southeast Asia. Low fat dairy consumption was higher
than whole fat dairy in North America and Europe, while
other regions of the world consumed markedly higher
whole fat than low fat dairy (table 1; online appendix
table S4). There were also marked differences in body
mass index, physical activity, and education among participants across regions, with body mass index being highest
in the Middle East and South America, physical activity
highest in South America, North America, and Europe,
and a college education most common in North America
and Europe.
At baseline, 78 533 (56%) individuals had elevated
blood pressure, 67 897 (48%) had elevated waist circumference, 63 415 (53%) had low HDL-C, 35 595 (30.2%)
had elevated triglycerides, and 33 082 (27.8%) had
elevated blood glucose. A total of 46 667 (41.3%) were
classified as having MetS (table 1).
Dairy intake and prevalence of metabolic syndrome
Higher dairy intake (at least two servings/day vs zero
intake) was associated with lower mean SBP and DBP,
waist circumference, body mass index, triglycerides, ratio
of triglycerides to HDL-C, and blood glucose, adjusting
for covariates (table 2). No significant association
between dairy intake and HDL-C levels was found, while
LDL cholesterol (LDL-C) levels were higher. There was
no significant association between dairy intake and other
cardiovascular risk markers (table 2).
Higher intakes of total dairy (OR 0.76, 95% CI 0.71 to
0.80, p-trend<0.0001), whole fat dairy alone (OR 0.72,
95% CI 0.66 to 0.78, p-trend<0.0001), and whole fat and
low fat dairy consumed jointly (OR 0.89, 95% CI 0.80 to
0.98, p-trend=0.0005) were each associated with a lower
prevalence of MetS, adjusting for covariates (figure 1).
No association between low fat dairy and prevalence of
MetS was found (OR 1.03, 95% CI 0.77 to 1.38).
Total dairy and whole fat dairy, but not low fat dairy,
were also associated with a lower prevalence of most MetS
components, including elevated blood pressure, elevated
waist circumference, elevated triglycerides, and elevated
blood glucose. No significant association was found for
low HDL-C with total, whole fat or low fat dairy (figure 1).
BMJ Open Diab Res Care 2020;8:e000826. doi:10.1136/bmjdrc-2019-000826
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22.0
27.9
50.2

42.8
37.8
19.4
2143 (816)

Primary school

Secondary school

College

Energy intake (Kcal), mean (SD)

3.4 (7.5)

42.1 (41.1)

111.5 (145.3)

4.9 (42.1)

16.8 (24.1)

48.5 (99.4)

196.3 (248.6)

76.4 (169.9)

188.0 (248.3)

264.4 (283.3)

2209 (797)

16.9

24.0

59.1

 

12,247/22,650
(54.1)

5.19 (1.75)

1.89 (1.32)

1.19 (0.29)

92.1 (13.3)

83.1 (23.3)

132.1 (22.8)

28.2 (5.5)

13 590 (57.3)

9163 (38.6)

51.4 (9.7)

0.3 (1.6)

0.7 (3.7)

3.7 (13.6)

86.9 (111.3)

11.8 (32.2)

85.7 (109.9)

90.5 (114.5)

2033 (950)

2.1

34.0

63.9

 

1,541/3,685
(41.8)

4.89 (2.61)

1.20 (0.78)

1.22 (0.42)

83.5 (15.6)

86.8 (15.7)

138.0 (27.0)

26.3 (7.3)

3001 (48.5)

1863 (30.1)

49.9 (10.6)

South America Africa
(n=23 717)
(n=6187)

2.7 (5.7)

16.1 (13.3)

185.2 (171.6)

87.3 (113.7)

94.9 (137.1)

140.6 (140.9)

296.5 (208.6)

2319 (829)

19.4

31.3

49.3

 

2,565/10,311
(24.9)

5.72 (2.37)

1.70 (1.09)

1.09 (0.28)

91.8 (13.1)

78.4 (11.4)

125.6 (19.4)

28.7 (5.5)

5974 (57.4)

4992 (47.9)

48.2 (9.4)

Middle East
(n=10 410)

2.3 (17.2)

2.7 (10.1)

89.8 (139.2)

52.3 (96.1)

31.0 (74.7)

138.6 (183.3)

146.6 (187.7)

2106 (826)

13.9

35.0

51.2

 

11,777/26,926
(43.7)

5.43 (2.64)

1.44 (0.93)

1.16 (0.35)

78.4 (13.4)

80.2 (12.9)

126.1 (21.3)

23.0 (4.9)

14 815 (48.4)

13 439 (43.9)

48.4 (10.3)

South Asia
(n=30 594)

0.6 (1.1)

5.2 (7.6)

0.24 (6.7)

35.0 (74.5)

1.5 (4.1)

34.9 (73.9)

35.6 (74.5)

2499 (1016)

13.8

45.8

40.4

 

3,689/11,070
(33.3)

5.37 (2.32)

1.73 (1.04)

1.19 (0.31)

86.2 (12.3)

81.4 (14.7)

136.5 (23.8)

26.0 (5.0)

5685 (48.6)

4886 (41.7)

51.9 (9.9)

Southeast Asia
(n=11 713)

NA

1.1 (7.3)

21.2 (58.8)

81.5 (16.5)

11.0 (48.0)

92.8 (136.0)

103.9 (140.1)

1964 (667)

14.8

51.1

34.1

 

18,938/44,834
(42.2)

5.32 (1.51)

1.46 (1.03)

1.18 (0.31)

81.1 (10.6)

82.8 (13.2)

133.5 (22.4)

24.6 (3.7)

22 063 (48.5)

19 031 (41.8)

51.0 (9.8)

China
(n=45 479)

*We categorized countries into seven regions based on similarities in dietary patterns: China, South Asia (India, Bangladesh, and Pakistan), North America and Europe (Canada, Poland,
and Sweden), South America (Argentina, Brazil, Chile, and Colombia), Middle East (Iran, occupied Palestine territory, Turkey, Saudi Arabia, and United Arab Emirates), South East Asia
(Philippines and Malaysia), and Africa (Tanzania, South Africa, and Zimbabwe).
†High (>3000 MET per min per week); MET=metabolic equivalents.
‡Low fat dairy was not recorded in two centers in India (Trivandrum and Jaipur), Malaysia, and South Africa.
§Butter intake was not recorded in China, Malaysia, the occupied Palestinian territory, and Sweden.
HDL-C, high density lipoprotein cholesterol; NA, not available.

12.3 (25.5)
3.3 (25.4)

Cheese

Butter§

192.9 (232.3)

105.7 (169.1)
66.2 (122.3)

Milk

Yogurt

124.6 (174.7)
65.0 (153.6)

Whole fat dairy

Low fat dairy‡

156.8 (168.3)
194.3 (240.5)

179.0 (224.1)

351.1 (272.9)

2266 (833)

Total dairy

Dairy intake (g/day), mean (SD)

 

 

Education status (%)

5.35 (1.35)
9,802/18,328
(53.5)

5.34 (1.91)
60,559/137,804
(43.9)

Blood glucose (mmol/L), mean (SD)

High physical activity (MET)†

1.41 (0.86)

1.36 (0.37)

1.20 (0.34)
1.54 (1.06)

HDL-C (mmol/L), mean (SD)

90.6 (14.1)

84.8 (13.7)

Waist circumference (cm), mean (SD)

Triglycerides (mmol/L), mean (SD)

81.9 (12.5)

81.9 (15.3)

Diastolic blood pressure (mm Hg), mean
(SD)

28.0 (5.4)

13 614 (69.0)
131.6 (20.9)

25.8 (5.3)

52.8 (9.3)
8631 (43.8)

Systolic blood pressure (mm Hg), mean (SD) 131.3 (22.4)

Body mass index (kg/m ), mean (SD)

78 742 (53.20

Urban (%)

2

50.6 (9.9)
62 005 (41.9)

Age (years), mean (SD)

Overall
(n=147 812)

North
America /
Europe
(n=19 712)

Characteristics of the study participants at enrollment overall and by regions (n=147 812)*

Male (%)

Table 1
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Table 2 Mean (SE) blood pressure, blood lipid and glucose concentrations by total dairy intake (n=147 812)
Adjusted means (SE)
Outcome

0 serving/day

0.01–1 serving/ 1.01–2 serving/
day
day
>2 serving/day

p-trend

Total dairy intake
Systolic blood pressure (mm Hg)

133.2 (0.74)

131.8 (0.73)

130.9 (0.74)

130.3 (0.74)

 <0.0001

Diastolic blood pressure (mm Hg)

83.8 (0.57)

82.7 (0.56)

82.2 (0.57)

81.8 (0.57)

 <0.0001

Waist circumference (cm)

85.8 (0.37)

85.7 (0.36)

85.5 (0.36)

85.2 (0.37)

 <0.0001

26.8 (0.33)

26.6 (0.32)

26.6 (0.32)

26.3 (0.33)

 <0.0001

2

Body mass index (kg/m )
HDL-C (mmol/L)

1.21 (0.016)

1.21 (0.016)

1.21 (0.016)

1.21 (0.016)

 0.133

Triglyceride (mmol/L)

1.55 (0.04)

1.55 (0.03)

1.53 (0.03)

1.49 (0.04)

 <0.0001

Fasting glucose (mmol/L)

5.33 (0.07)

5.34 (0.07)

5.30 (0.07)

5.26 (0.07)

 0.001

Total cholesterol (mmol/L)

4.87 (0.05)

4.91 (0.05)

4.91 (0.05)

4.89 (0.05)

 0.170

LDL-C (mmol/L)

3.03 (0.05)

3.08 (0.05)

3.08 (0.05)

3.06 (0.05)

 0.03

Total cholesterol to HDL-C ratio

4.22 (0.06)

4.25 (0.06)

4.26 (0.06)

4.24 (0.06)

 0.16

Triglyceride to HDL-C ratio

1.45 (0.04)

1.44 (0.04)

1.44 (0.04)

1.40 (0.04)

 0.02

ApoA1 (µmol/L)

1.50 (0.02)

1.50 (0.02)

1.49 (0.02)

1.49 (0.02)

 0.06

ApoB (µmol/L)
ApoA to ApoB ratio

1.00 (0.01)
0.70 (0.02)

1.02 (0.01)
0.71 (0.01)

1.02 (0.01)
0.71 (0.01)

1.00 (0.01)
0.70 (0.01)

 0.03
 0.59

Mean systolic and diastolic blood pressure were adjusted for age, sex, body mass index, blood pressure medication, smoking, location
(urban/rural), education, physical activity, fruit and vegetable intake, percent energy from carbohydrates, energy and study center as random
effect.
Mean waist circumferences was adjusted for age (continuous), sex, BMI (continuous), smoking, location (urban/rural), education, physical
activity, energy intake, quintiles of fruits and vegetables, percent energy from carbohydrates consumption, and study center as random
effect.
Mean body mass index was adjusted for age (continuous), sex, smoking, location (urban/rural), education, physical activity, energy intake,
quintiles of fruits and vegetables, percent energy from carbohydrates consumption, and study center as random effect.
Mean HDL-C was adjusted for age (continuous), sex, body mass index (continuous), smoking, cholesterol and statin medication, location
(urban/rural), education, physical activity, energy intake, quintiles of fruits and vegetables, percent energy from carbohydrates consumption,
and study center as random effect.
Mean triglyceride was adjusted for age (continuous), sex, body mass index (continuous), smoking, statin medication, location (urban/rural),
education, physical activity, energy intake, quintiles of fruits and vegetables, percent energy from carbohydrates consumption, and study
center as random effect.
Mean fasting blood glucose was adjusted for age (continuous), sex, body mass index (continuous), smoking, diabetes medication, location
(urban/rural), education, physical activity, energy intake, quintiles of fruits and vegetables, percent energy from carbohydrates consumption,
and study center as random effect.
Mean total cholesterol, LDL-C, total cholesterol to HDL-C ratio, ApoA, ApoB, ApoA to ApoB ratio were adjusted for age, sex, body mass
index, cholesterol medication, education, location (urban/rural), physical activity, energy intake, quintiles of fruits and vegetables, percent
energy from carbohydrates consumption, and study center as random effect.
Apo, apolipoprotein; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

With mutual adjustment of whole fat dairy and low fat
dairy, higher whole fat dairy intake was associated with
lower prevalence of MetS. By contrast, higher intake of low
fat dairy was associated with a modestly higher prevalence
of MetS (p-trend=0.05) and low HDL-C (p-trend=0.001),
but also with a marginally lower prevalence of elevated
triglycerides (p-trend=0.04) (online appendix table S5).
Types of dairy foods (milk, yogurt, cheese, and butter)
showed similar associations with lower MetS prevalence
(online appendix figure S1).
The associations between dairy intake and MetS were
consistent in regions with low dairy intake (China,
South Asia, Southeast Asia, and Africa) and high
dairy intake (North America/Europe, Middle East,
and South America), but the magnitude of the association was stronger in the low dairy regions (p for
6

heterogeneity=0.017) (online appendix figure S2). The
association between dairy intake and MetS was independent of sodium and potassium intake (online appendix
figure S3).
Dairy intake and risk of incident hypertension and diabetes
Of the 57 547 individuals without hypertension at baseline, a total of 13 640 (23.7%) people with incident hypertension were identified during follow-up. A total of 5351
(4.1%) people with incident diabetes were identified
during follow-up among the 131 481 individuals without
diabetes.
Higher dairy intake (at least two servings/day vs zero
intake) was associated with a lower incidence of hypertension (HR 0.89, 95% CI 0.82 to 0.97, Pp-trend=0.02)
BMJ Open Diab Res Care 2020;8:e000826. doi:10.1136/bmjdrc-2019-000826
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Figure 1 Association of (A) total dairy, (B) whole fat dairy alone, (C) low fat dairy alone and (D) among those who consumed
both whole fat and low fat dairy with prevalent metabolic syndrome and its component (OR, 95% CI). Metabolic syndrome:
defined as presence of any three of the four components: elevated blood pressure (defined as those on blood pressure
lowering medication, or systolic blood pressure) ≥130 mm Hg or diastolic blood pressure (DBP) ≥85 mm Hg); elevated waist
circumference (defined as women with waist >80 cm, men with waist ≥94 cm, except among Asians or South Americans
in whom waist was ≥90 cm), reduced high density lipoprotein cholesterol (HDL-C) (defined as men on cholesterol lowering
medications or with HDL-C<1 mmol/dL (40 mg/dL), or women with HDL-C<1.3 mmol/L (50 mg/dL)); elevated triglycerides
(defined as triglyceride levels>1.7 mmmol/dL (150 mg/dL)); and elevated fasting blood glucose (defined as as those on
glucose lowering medications or with a fasting glucose value ≥5.5 mmol/L). OR models for metabolic syndrome and waist
circumference are adjusted for age (continuous), sex, smoking status, education, location, physical activity, energy intake,
percent energy from carbohydrate, fruit and vegetable intake, and study center as random effect. Models for whole dairy intake
are adjusted for low fat dairy intake and vice versa. OR model for elevated blood pressure, low HDL-C, elevated triglycerides
and elevated fasting blood glucose are adjusted for age (continuous), sex, body mass index (continuous), smoking status,
location, education, physical activity, energy intake, quintiles of percent energy from carbohydrate, fruit and vegetable intake,
and study center as random effect. Models for whole dairy intake are adjusted for low fat dairy intake and vice versa. Panel (A)
shows a significant inverse association between total dairy intake and metabolic syndrome and each of its components, except
low HDL-C (no association); (B) shows a significant inverse association between whole fat dairy (alone) intake and metabolic
syndrome, elevated blood pressure, elevated waist circumference, elevated triglycerides, and elevated fasting blood glucose.
No association was observed between whole fat dairy and low HDL-C; (C) shows no association between low fat dairy (alone)
intake and metabolic syndrome and its components, except elevated triglycerides and elevated fasting blood glucose (a trend
towards lower prevalence); and (D) shows a significant inverse association between consumption of both whole fat and low
fat dairy and metabolic syndrome, elevated blood pressure and elevated triglycerides, and no association with elevated waist
circumference or HDL-C or elevated fasting blood glucose.
BMJ Open Diab Res Care 2020;8:e000826. doi:10.1136/bmjdrc-2019-000826
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Figure 2 Associations of (A) total dairy, (B) whole fat dairy alone, (C) low fat dairy alone, and (D) both whole fat and low
fat dairy with incident hypertension and incident diabetes (HR, 95% CI). Incident hypertension was defined as self-reported
hypertension, with or without use of antihypertensive medications or a systolic blood pressure of >140 mm Hg, or a diastolic
blood pressure of >90 mm Hg.10 Incident diabetes was defined as self-reported diabetes, with or without use of oral
hypoglycemic agents or insulin, or having a documented fasting glucose level of ≥7.0 mmol/L.11 Hypertension model adjusted
for age (continuous), sex, body mass index (continuous), education, smoking status, location, physical activity, energy,
quintiles of percent energy from carbohydrates, fruit and vegetable intake and study center as random effect. Models for
whole dairy intake adjusted for low fat dairy intake and vice versa. Diabetesmodel adjusted for age (continuous), sex, body
mass index (continuous), education, smoking status, location, family history of diabetes, physical activity, energy, quintiles
of percent energy from carbohydrates, fruit and vegetable intake, and study center as random effect. Models for whole dairy
intake are adjusted for low fat dairy intake and vice versa. Panel (A) shows a significant inverse association between total dairy
and incident hypertension and a trend towards lower incidence of diabetes; (B) shows a trend towards lower incidence of
hypertension and diabetes with higher intake of whole fat dairy (alone); (C) shows no association between low fat dairy intake
(alone) and incident hypertension and incident diabetes; and (D) shows a trend towards lower incidence of hypertension and
diabetes with higher intake of both whole fat and low fat dairy.

(figure 2) with directionally similar estimates found for
whole fat and low fat dairy.
For diabetes, higher dairy intake (at least two servings/
day vs zero intake) was associated with a lower diabetes
incidence (HR 0.88, 95% CI 0.76 to 1.02, p-trend=0.01)
(figure 2) with directionally similar estimates with whole
fat dairy (alone or with low fat) but not with low fat dairy
alone.
8

When we used more than three servings/day as the
highest intake category (instead of more than two
servings/day), we found similar estimates of association (for hypertension, HR 0.87,; 95% CI 0.79 to 0.96,
p-trend=0.02; and for diabetes, HR 0.86, 95% CI 0.73 to
1.02;, p-trend=0.01).
When we evaluated whole fat dairy intake and low fat
dairy intake jointly adjusted for each other, higher whole
BMJ Open Diab Res Care 2020;8:e000826. doi:10.1136/bmjdrc-2019-000826

Epidemiology/Health Services Research
fat dairy intake was significantly associated with a lower
incidence of hypertension and diabetes. In contrast, no
significant associations were found for low fat dairy versus
hypertension or diabetes (online appendix table S5).
The associations between types of dairy (milk, yogurt,
cheese, and butter) showed directionally similar results
with incident hypertension and incident diabetes (online
appendix figure S4).
Discussion
In this large multinational prospective cohort study from
21 countries located in five continents, higher dairy
consumption was associated with lower mean blood
pressure, waist circumference, triglycerides, and blood
glucose. Additionally, total dairy and whole fat dairy
intakes were associated with lower risk of MetS and its
components. A similar pattern of results was found in
those consuming diets that may influence blood pressure, such as those with higher or lower levels of sodium
and potassium, or varying levels of fruit and vegetable
intake. During follow-up of nine years, higher consumption of dairy was associated with lower risk of incident
hypertension and incident diabetes. These results were
clearer in those who consumed whole fat dairy than in
those who consumed low fat dairy.
Short-term feeding trials showed a reduction in blood
pressure with both low and whole fat dairy, and a reduction in triglycerides with whole fat,6 7 22 but the evidence
for fasting blood glucose in these trials is inconsistent or
inconclusive.8 9 Our results showed directionally consistent inverse associations between consumption of various
types of dairy foods (milk, yogurt, cheese, or butter) and
MetS, especially for intake of whole fat dairy. Our findings are consistent with recent meta-analyses of cohort
studies of mostly Western and higher-income Asian populations (~10% lower risk of MetS per one serving increase
in dairy).11 23–25 Further, in these meta-analyses the associations were clearer for whole fat dairy (RR 0.78, 95% CI
0.61 to 0.96), while no association was observed for low
fat dairy and MetS,11 which is consistent with our findings. In addition, a recent cohort study in Brazil found
similar results.26
Our finding of a favorable association between butter
and prevalence of MetS should be interpreted with
caution, given that butter intake was very low (mean
3.3 g/day). It is also noteworthy that butter was not
included as one of the dairy products in the total dairy
definition in our analyses, and so even if the association
of butter with lower MetS is due to chance, the results on
total dairy are robust.
In prospective analyses, we identified a significant
inverse association between dairy intake and incident
hypertension, which is consistent with a recent meta-
analysis of cohort studies in mostly Western and some
Asian populations,5 12 23 27 two short-
term controlled
feeding trials of dairy intake and blood pressure,6 7 and
our prior report of lower risk of stroke with higher dairy
BMJ Open Diab Res Care 2020;8:e000826. doi:10.1136/bmjdrc-2019-000826

consumption.28 Cohort studies in the US and Europe
have found an association with lower risk of hypertension
with higher dairy intake, especially yogurt.29 30 On the
other hand, recent Mendelian randomization studies did
not show that dairy intake is associated with lower hypertension.31 Taken together, dairy foods should be evaluated in large randomized trials of dairy intake and longer
term blood pressure change or risk of hypertension.
Our findings of an inverse association of total dairy and
different types of dairy products with incident diabetes
are consistent with most32–34 but not all35 previous meta-
analyses. The meta-analysis by Chen et al35 represented
mostly high-income countries and more homogeneous
populations, whereas PURE covers substantially more
diverse populations and broad patterns of diet globally.
Further, high income countries consume higher amounts
of dairy (mainly low fat) than other parts of the world. The
background diet also varies across countries, whereby in
high income countries the major problem is over nutrition, while in low income countries, there is more under
nutrition and people consume low amounts of dairy and
a higher amount of refined carbohydrates. Therefore, the
findings from a previous meta-analysis may not be applicable to other parts of the world, although our findings
were robust in different populations with varying levels
of dairy intake. In a recent meta-
analysis, blood fatty
acids commonly found in dairy foods were associated
with lower diabetes risk.36 However, a recent Mendelian
randomization study did not find support for an association of milk intake with diabetes risk.37 Collectively, the
evidence suggests a need for large randomized trials of
dairy intake, including an evaluation of different types
of dairy (fermented vs non-fermented) and fat content
(whole fat vs low fat) in relation to incident diabetes.
Possible pathways for metabolic benefits of dairy
include angiotensin converting enzyme, peroxisome
proliferator activated receptors, hepatic de novo lipogenesis, hepatic and adipose fatty acid oxidation, and
inflammation.10 Further, bioactive peptides or amino
acids produced through yogurt or cheese fermentation
improves insulin sensitivity, while branched chain amino
acids in whey has been shown to improve postprandial
insulin response.38
Our study is among the first large multinational cohort
studies to examine the association of dairy intake with
prevalence of MetS and risk of diabetes and hypertension. We used standardized methods to measure diet
using country specific validated FFQs and standardized
methods to obtain information on health measures and
record new cases of hypertension and diabetes during
follow-up.
There are some potential limitations. First, diet was
self-reported and variations in reporting might lead to
random errors that could dilute real associations between
dairy intake and health outcomes. Further, misclassification of dairy intake cannot be ruled out as we did not
have repeat measures of diet. However, we found that
the association between milk intake, recorded at three
9
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years of follow-up, and cardiovascular disease was similar
to the analyses using the baseline information,19 indicating that repeat dietary measures are unlikely to alter
our findings. Second, we could not assess incident MetS
as several of its components (waist circumference, blood
glucose, and blood lipids) were assessed in only a random
20% of the study population during follow-up. For the
analyses of dairy versus incident hypertension, 25 287
individuals were excluded because blood pressure was
not recorded in all participants during follow-up. The
blood pressure measures during follow-up were carried
out systematically in all participants in 16 countries or in
a random 20% of participants in five countries. The characteristics of individuals without blood pressure measures
during follow-up compared with individuals with blood
pressure measures during follow-up were similar (online
appendix table S2). Third, the possibility of residual
confounding cannot be completely ruled out in observational studies (eg, dairy intake might be a proxy for
poverty or access to healthcare). However, our results
persisted despite extensive adjustments for all known
confounders, including the use of five markers of socioeconomic status (education, wealth, occupation, urban/
rural location, and geographical location). Additionally,
we adjusted for study center as a random effect, which
takes into account socioeconomic factors and clustering
by community, leading to comparisons within countries
(see supplemental methods in the online supplementary appendix). Lastly, the impact of higher dairy intake
may be influenced by the overall diet, even though analyses are adjusted for multiple dietary confounders and
conducted within different strata. However, the consistency of results across regions with markedly different
levels of dairy intake makes it less likely that confounders
including the background diet, which are expected to
vary in different regions, explain our observations.
In conclusion, we report that intake of dairy products,
especially whole fat products, is associated with lower
prevalence of MetS and its individual components at
baseline, and a lower risk of hypertension and diabetes
during follow-up. If our findings are confirmed in sufficiently large and long term trials, then increasing dairy
consumption may represent a feasible and low cost
approach to reducing MetS, hypertension, diabetes, and
ultimately cardiovascular disease events worldwide.
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